- Home
- ROST vs REGN Comparison
ROST vs REGN Comparison
Compare ROST & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROST | REGN |
|---|---|---|
| Founded | 1982 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.4B | 81.1B |
| IPO Year | 1994 | 1995 |
Fundamental Metrics
Financial Performance| Metric | ROST | REGN |
|---|---|---|
| Price | $223.13 | $732.05 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 27 |
| Target Price | $270.56 | ★ $853.19 |
| AVG Volume (30 Days) | ★ 1.7M | 583.4K |
| Earning Date | 11-19-2026 | 10-30-2026 |
| Dividend Yield | ★ 0.79% | 0.52% |
| EPS Growth | 4.59 | ★ 8.19 |
| EPS | 4.69 | ★ 18.95 |
| Revenue | ★ $22,750,559,000.00 | $5,872,227,000.00 |
| Revenue This Year | $13.01 | $18.62 |
| Revenue Next Year | $6.83 | $8.80 |
| P/E Ratio | $48.24 | ★ $38.33 |
| Revenue Growth | 7.67 | ★ 20.82 |
| 52 Week Low | $147.49 | $541.00 |
| 52 Week High | $257.00 | $859.34 |
Technical Indicators
Market Signals| Indicator | ROST | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 36.40 | 36.57 |
| Support Level | $206.90 | $732.04 |
| Resistance Level | $230.42 | $782.44 |
| Average True Range (ATR) | 4.57 | 19.95 |
| MACD | -0.34 | -8.10 |
| Stochastic Oscillator | 7.99 | 14.29 |
Price Performance
Historical ComparisonAbout ROST Ross Stores Inc.
Ross Stores, founded in 1982, is a US-focused off-price apparel and home fashion retailer operating more than 2,100 stores across 43 states, primarily under the Ross Dress for Less banner, with a smaller footprint through dd's Discounts. In fiscal 2025, the company generated over $22 billion in sales. Ross offers branded apparel, footwear, accessories, and home goods at a 20%-60% discount to department and specialty store prices, sourcing closeouts and excess inventory from vendors worldwide.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.